{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:46:19Z","timestamp":1777355179566,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40259-021-00511-9","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T06:03:21Z","timestamp":1638165801000},"page":"41-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin"],"prefix":"10.1007","volume":"36","author":[{"given":"Andreas","family":"Volk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Covini-Souris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Kuehnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"De Mey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"R\u00f6misch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"511_CR1","unstructured":"Nobel Media AB 2021. The Nobel Prize in Physiology or Medicine 1901. 1901. https:\/\/www.nobelprize.org\/prizes\/medicine\/1901\/summary\/. Accessed 6 Jun 2021."},{"key":"511_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102790","volume":"59","author":"BL Brown","year":"2020","unstructured":"Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59: 102790. https:\/\/doi.org\/10.1016\/j.transci.2020.102790.","journal-title":"Transfus Apher Sci"},{"key":"511_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/life11020144","author":"D Focosi","year":"2021","unstructured":"Focosi D, Tuccori M, Franchini M. The road towards polyclonal anti-SARS-CoV-2 immunoglobulins (Hyperimmune Serum) for passive immunization in COVID-19. Life (Basel). 2021. https:\/\/doi.org\/10.3390\/life11020144.","journal-title":"Life (Basel)"},{"key":"511_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","volume":"20","author":"L Chen","year":"2020","unstructured":"Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398\u2013400. https:\/\/doi.org\/10.1016\/S1473-3099(20)30141-9.","journal-title":"Lancet Infect Dis"},{"key":"511_CR5","unstructured":"Food and Drug Administration. Emergency Use Authorization of Covid-19 convalescent plasma."},{"key":"511_CR6","doi-asserted-by":"publisher","DOI":"10.2196\/25500","volume":"7","author":"HT Peng","year":"2021","unstructured":"Peng HT, Rhind SG, Beckett A. convalescent plasma for the prevention and treatment of COVID-19: a systematic review and quantitative analysis. JMIR Public Health Surveill. 2021;7: e25500. https:\/\/doi.org\/10.2196\/25500.","journal-title":"JMIR Public Health Surveill"},{"key":"511_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.mayocpiqo.2021.01.010","volume":"5","author":"M Franchini","year":"2021","unstructured":"Franchini M, Glingani C, Morandi M, Corghi G, Cerzosimo S, Beduzzi G, et al. Safety and efficacy of convalescent plasma in Elderly COVID-19 patients: the RESCUE trial. Mayo Clin Proc Innov Qual Outcomes. 2021;5:403\u201312. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2021.01.010.","journal-title":"Mayo Clin Proc Innov Qual Outcomes."},{"key":"511_CR8","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1080\/01621459.1999.10474144","volume":"12","author":"A Gharbharan","year":"2021","unstructured":"Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021;12:3189. https:\/\/doi.org\/10.1080\/01621459.1999.10474144.","journal-title":"Nat Commun"},{"key":"511_CR9","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.mayocp.2021.02.008","volume":"96","author":"SA Klassen","year":"2021","unstructured":"Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc. 2021;96:1262\u201375. https:\/\/doi.org\/10.1016\/j.mayocp.2021.02.008.","journal-title":"Mayo Clin Proc"},{"key":"511_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","volume":"384","author":"MJ Joyner","year":"2021","unstructured":"Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from covid-19. N Engl J Med. 2021;384:1015\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2031893.","journal-title":"N Engl J Med"},{"key":"511_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa2033700","volume":"384","author":"R Libster","year":"2021","unstructured":"Libster R, P\u00e9rez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2033700.","journal-title":"N Engl J Med"},{"key":"511_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, V\u00e1zquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2031304.","journal-title":"N Engl J Med"},{"key":"511_CR13","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1101\/2020.08.24.264630","volume":"223","author":"BL Haagmans","year":"2020","unstructured":"Haagmans BL, Noack D, Okba NMA, Li W, Wang C, Bestebroer T, et al. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model. J Infect Dis. 2020;223:2020\u20138. https:\/\/doi.org\/10.1101\/2020.08.24.264630.","journal-title":"J Infect Dis"},{"key":"511_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y","author":"RE Chen","year":"2021","unstructured":"Chen RE, Winkler ES, Case JB, Aziati ID, Bricker TL, Joshi A, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021. https:\/\/doi.org\/10.1038\/s41586-021-03720-y.","journal-title":"Nature"},{"key":"511_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-2456-9","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590:630\u20134. https:\/\/doi.org\/10.1038\/s41586-020-2456-9.","journal-title":"Nature"},{"key":"511_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8828","author":"MS Cohen","year":"2021","unstructured":"Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA. 2021. https:\/\/doi.org\/10.1001\/jama.2021.8828.","journal-title":"JAMA"},{"key":"511_CR17","unstructured":"Alexandra Bowie. Regeneron Reports Positive Interim Data with REGEN-COV\u2122 Antibody Cocktail used as Passive Vaccine to Prevent COVID-19. TARRYTOWN, N.Y., USA; January 26, 2021."},{"key":"511_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029","author":"D Hagin","year":"2021","unstructured":"Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.029.","journal-title":"J Allergy Clin Immunol"},{"key":"511_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01046-y","author":"H Kinoshita","year":"2021","unstructured":"Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, et al. Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency. J Clin Immunol. 2021. https:\/\/doi.org\/10.1007\/s10875-021-01046-y.","journal-title":"J Clin Immunol"},{"key":"511_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejca.2021.03.030","volume":"150","author":"D Tougeron","year":"2021","unstructured":"Tougeron D, Hentzien M, Seitz-Polski B, Bani-Sadr F, Bourhis J, Ducreux M, et al. Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). Eur J Cancer. 2021;150:232\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.030.","journal-title":"Eur J Cancer"},{"key":"511_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3466","volume":"13","author":"A Durandy","year":"2013","unstructured":"Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol. 2013;13:519\u201333. https:\/\/doi.org\/10.1038\/nri3466.","journal-title":"Nat Rev Immunol"},{"key":"511_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","volume":"147","author":"I Meyts","year":"2021","unstructured":"Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147:520\u201331. https:\/\/doi.org\/10.1016\/j.jaci.2020.09.010.","journal-title":"J Allergy Clin Immunol"},{"key":"511_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10875-020-00928-x","volume":"41","author":"S Delavari","year":"2021","unstructured":"Delavari S, Abolhassani H, Abolnezhadian F, Babaha F, Iranparast S, Ahanchian H, et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. J Clin Immunol. 2021;41:345\u201355. https:\/\/doi.org\/10.1007\/s10875-020-00928-x.","journal-title":"J Clin Immunol"},{"issue":"Suppl 15","key":"511_CR24","first-page":"S3","volume":"14","author":"JM Dwyer","year":"1996","unstructured":"Dwyer JM. Immunoglobulins in autoimmunity: history and mechanisms of action. Clin Exp Rheumatol. 1996;14(Suppl 15):S3-7.","journal-title":"Clin Exp Rheumatol"},{"key":"511_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1542\/pir.16.11.403","volume":"16","author":"S Ramesh","year":"1995","unstructured":"Ramesh S, Schwartz SA. Therapeutic uses of intravenous immunoglobulin (IVIG) in children. Pediatr Rev. 1995;16:403\u201310 (quiz 410).","journal-title":"Pediatr Rev"},{"key":"511_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/00006454-199707000-00012","volume":"16","author":"ER Stiehm","year":"1997","unstructured":"Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J. 1997;16:696\u2013707. https:\/\/doi.org\/10.1097\/00006454-199707000-00012.","journal-title":"Pediatr Infect Dis J"},{"key":"511_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40259-017-0212-y","volume":"31","author":"KU Radomski","year":"2017","unstructured":"Radomski KU, Lattner G, Schmidt T, R\u00f6misch J. Pathogen safety of a new intravenous immune globulin 10% liquid. BioDrugs. 2017;31:125\u201334. https:\/\/doi.org\/10.1007\/s40259-017-0212-y.","journal-title":"BioDrugs"},{"key":"511_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.5414\/CP202782","volume":"54","author":"W Frenzel","year":"2016","unstructured":"Frenzel W, Wietek S, Svae T-E, Debes A, Svorc D. Tolerability and safety of Octagam\u00ae (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016;54:847\u201355. https:\/\/doi.org\/10.5414\/CP202782.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"511_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/trf.16291","volume":"61","author":"M Karbiener","year":"2021","unstructured":"Karbiener M, Farcet MR, Ilk R, Schreiner J, Lenart J, Powers N, et al. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations. Transfusion. 2021;61:1141\u20137. https:\/\/doi.org\/10.1111\/trf.16291.","journal-title":"Transfusion"},{"key":"511_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab142","author":"MR Farcet","year":"2020","unstructured":"Farcet MR, Karbiener M, Schwaiger J, Ilk R, Kreil TR. Rapidly increasing SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic. J Infect Dis. 2020. https:\/\/doi.org\/10.1093\/infdis\/jiab142.","journal-title":"J Infect Dis"},{"key":"511_CR31","doi-asserted-by":"publisher","DOI":"10.2450\/2021.0055-21","author":"G Pisani","year":"2021","unstructured":"Pisani G, Cristiano K, Simeoni M, Martina A, Pati I, Carocci A, et al. Detection of antibodies against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins produced from plasma collected in Italy during the pandemic. Blood Transfus. 2021. https:\/\/doi.org\/10.2450\/2021.0055-21.","journal-title":"Blood Transfus"},{"key":"511_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16378","author":"P Vandeberg","year":"2021","unstructured":"Vandeberg P, Cruz M, Diez JM, Merritt WK, Santos B, Trukawinski S, et al. Brief report: production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Transfusion. 2021. https:\/\/doi.org\/10.1111\/trf.16378.","journal-title":"Transfusion"},{"key":"511_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2217\/imt-2020-0263","volume":"13","author":"S Ali","year":"2021","unstructured":"Ali S, Uddin SM, Ali A, Anjum F, Ali R, Shalim E, et al. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. Immunotherapy. 2021;13:397\u2013407. https:\/\/doi.org\/10.2217\/imt-2020-0263.","journal-title":"Immunotherapy"},{"key":"511_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejps.2018.03.007","volume":"118","author":"IR Melamed","year":"2018","unstructured":"Melamed IR, Borte M, Trawnicek L, Kobayashi A-L, Kobayashi RH, Knutsen A, et al. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. Eur J Pharm Sci. 2018;118:80\u20136. https:\/\/doi.org\/10.1016\/j.ejps.2018.03.007.","journal-title":"Eur J Pharm Sci"},{"key":"511_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1473-3099(15)70090-3","volume":"581","author":"R W\u00f6lfel","year":"2020","unstructured":"W\u00f6lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, M\u00fcller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(15)70090-3.","journal-title":"Nature"},{"key":"511_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","volume":"397","author":"PA Kristiansen","year":"2021","unstructured":"Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397:1347\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(21)00527-4.","journal-title":"Lancet"},{"key":"511_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/978-1-4939-0758-8_26","volume":"1161","author":"PC Gauger","year":"2014","unstructured":"Gauger PC, Vincent AL. Serum virus neutralization assay for detection and quantitation of serum-neutralizing antibodies to influenza A virus in swine. Methods Mol Biol. 2014;1161:313\u201324. https:\/\/doi.org\/10.1007\/978-1-4939-0758-8_26.","journal-title":"Methods Mol Biol"},{"key":"511_CR38","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1016\/j.vaccine.2010.02.092","volume":"28","author":"KK Orlinger","year":"2010","unstructured":"Orlinger KK, Holzer GW, Schwaiger J, Mayrhofer J, Schmid K, Kistner O, et al. An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system. Vaccine. 2010;28:3318\u201324. https:\/\/doi.org\/10.1016\/j.vaccine.2010.02.092.","journal-title":"Vaccine"},{"key":"511_CR39","volume-title":"Grundz\u00fcge biologische-medizinischer Statistik","author":"L Cavalli-Sforza","year":"1972","unstructured":"Cavalli-Sforza L. Grundz\u00fcge biologische-medizinischer Statistik. 3rd ed. Stuttgart: Gustav Fischer Verlag; 1972.","edition":"3"},{"key":"511_CR40","unstructured":"Centers for Disease Control and Prevention. CDC Covid Data Tracker. 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#national-lab. Accessed 2 Jun 2021."},{"key":"511_CR41","unstructured":"United States Census Bureau. U.S. and World Population Clock. https:\/\/www.census.gov\/popclock\/. Accessed 2 Jun 2021."},{"key":"511_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/v13020247","author":"GJ Walker","year":"2021","unstructured":"Walker GJ, Naing Z, Ospina Stella A, Yeang M, Caguicla J, Ramachandran V, et al. SARS Coronavirus-2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13020247.","journal-title":"Viruses"},{"key":"511_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/jalm\/jfaa188","volume":"6","author":"J Rychert","year":"2021","unstructured":"Rychert J, Couturier MR, Elgort M, Lozier BK, La\u2019ulu S, Genzen JR, et al. Evaluation of 3 SARS-CoV-2 IgG antibody assays and correlation with neutralizing antibodies. J Appl Lab Med. 2021;6:614\u201324. https:\/\/doi.org\/10.1093\/jalm\/jfaa188.","journal-title":"J Appl Lab Med."},{"key":"511_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104512","volume":"129","author":"AJ J\u00e4\u00e4skel\u00e4inen","year":"2020","unstructured":"J\u00e4\u00e4skel\u00e4inen AJ, Kuivanen S, Kek\u00e4l\u00e4inen E, Ahava MJ, Loginov R, Kallio-Kokko H, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol. 2020;129: 104512. https:\/\/doi.org\/10.1016\/j.jcv.2020.104512.","journal-title":"J Clin Virol"},{"key":"511_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2217\/imt-2020-0220","volume":"12","author":"J-M D\u00edez","year":"2020","unstructured":"D\u00edez J-M, Romero C, Vergara-Alert J, Bell\u00f3-Perez M, Rodon J, Honrubia JM, et al. Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins. Immunotherapy. 2020;12:1247\u201355. https:\/\/doi.org\/10.2217\/imt-2020-0220.","journal-title":"Immunotherapy"},{"key":"511_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh3826","author":"H Kalish","year":"2021","unstructured":"Kalish H, Klumpp-Thomas C, Hunsberger S, Baus HA, Fay MP, Siripong N, et al. Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abh3826.","journal-title":"Sci Transl Med"},{"key":"511_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15161","author":"JM Jones","year":"2021","unstructured":"Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021. JAMA. 2021. https:\/\/doi.org\/10.1001\/jama.2021.15161.","journal-title":"JAMA"},{"key":"511_CR48","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2\u2014Preliminary report. N Engl J Med. 2020;383:1920\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2022483.","journal-title":"N Engl J Med"},{"key":"511_CR49","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"key":"511_CR50","doi-asserted-by":"publisher","DOI":"10.1198\/jcgs.2009.07130","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021. https:\/\/doi.org\/10.1198\/jcgs.2009.07130.","journal-title":"Nat Med"},{"key":"511_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15918","author":"L Li","year":"2020","unstructured":"Li L, Tong X, Chen H, He R, Lv Q, Yang R, et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion. 2020. https:\/\/doi.org\/10.1111\/trf.15918.","journal-title":"Transfusion"},{"key":"511_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16401","author":"MA Vickers","year":"2021","unstructured":"Vickers MA, Sariol A, Leon J, Ehlers A, Locher AV, Dubay KA, et al. Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors. Transfusion. 2021. https:\/\/doi.org\/10.1111\/trf.16401.","journal-title":"Transfusion"},{"key":"511_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg9175","author":"L Stamatatos","year":"2021","unstructured":"Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021. https:\/\/doi.org\/10.1126\/science.abg9175.","journal-title":"Science"},{"key":"511_CR54","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41467-021-21111-9","volume":"12","author":"S Marot","year":"2021","unstructured":"Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021;12:844. https:\/\/doi.org\/10.1038\/s41467-021-21111-9.","journal-title":"Nat Commun"},{"key":"511_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223","author":"D Sterlin","year":"2021","unstructured":"Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Cla\u00ebr L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abd2223.","journal-title":"Sci Transl Med"},{"key":"511_CR56","doi-asserted-by":"publisher","unstructured":"D\u00edez JM, Romero C, Gajardo R. Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products. online: bioRxiv; 2021. https:\/\/doi.org\/10.1101\/2021.07.23.453571.","DOI":"10.1101\/2021.07.23.453571"},{"key":"511_CR57","doi-asserted-by":"publisher","unstructured":"Kai Wu, Angela Choi, Matthew Koch, LingZhi Ma, Anna Hill, Naveen Nunna, Wenmei Huang, Judy Oestreicher, Tonya Colpitts, Hamilton Bennett, Holly Legault, Yamuna Paila, Biliana Nestorova, Baoyu Ding, Rolando Pajon, Jacqueline M Miller, Brett Leav, Andrea Carfi, Roderick McPhee, Darin K Edwards. Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. medRxiv. 2021: Preprint. https:\/\/doi.org\/10.1101\/2021.05.05.21256716.","DOI":"10.1101\/2021.05.05.21256716"},{"issue":"803\u201319","key":"511_CR58","doi-asserted-by":"publisher","first-page":"ix","DOI":"10.1016\/j.iac.2008.06.006","volume":"28","author":"FA Bonilla","year":"2008","unstructured":"Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin N Am. 2008;28(803\u201319):ix. https:\/\/doi.org\/10.1016\/j.iac.2008.06.006.","journal-title":"Immunol Allergy Clin N Am"},{"key":"511_CR59","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.xcrm.2021.100204","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593:142\u20136. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100204.","journal-title":"Nature"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-021-00511-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T08:01:03Z","timestamp":1644912063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-021-00511-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1007\/s40259-021-00511-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.13.456066","asserted-by":"object"}]},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"10 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Octapharma Pharmazeutika Produktionsgesellschaft m.b.H., Austria and Octapharma Biopharmaceuticals GmbH, Germany, and Octapharma Plasma Inc., USA were the funding source. Octapharma Plasma Inc. was involved in plasma donation collection. Octapharma Pharmazeutika Produktionsgesellschaft m.b.H. and Octapharma Biopharmaceuticals GmbH were involved in analysis and data generation. Octapharma Pharmazeutika Produktionsgesellschaft m.b.H. covered all costs incurred for the present publication. ACPS-Network GmbH was paid for their pharmacokinetic analysis services by Octapharma Biopharmaceuticals GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AV, CCS, DK, JR, and TS are employed by companies that are part of the Octapharma group. CDM is owner and CEO of ACPS and received payment by Octapharma for the services involved in the preparation of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Octagam<sup>\u00ae<\/sup>, Cutaquig<sup>\u00ae<\/sup> and Panzyga<sup>\u00ae<\/sup> are trademarks of the Octapharma group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademarks"}},{"value":"Material that is still in existence and owned by Octapharma can be made available in principle for research purposes by non-profit organizations upon justified request. WHO International Standard was obtained from NIBSC, Potters Bar, UK (see materials and methods section) [\n                      \n                      ]. All data except epidemiologic data on seroconversion generated or analyzed during this study are included in this published article and its supplementary information files. Epidemiologic data on United States status of vaccination and COVID-19 cumulated cases were obtained from the CDC Data Tracker website [\n                      \n                      ].","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All plasma donations analyzed in this study were obtained after informed consent of the donors. Plasma products analyzed within this study were produced from material donated after informed consent for the purpose of producing pharmaceutical products.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Andreas Volk, Caroline Covini-Souris, Christian de Mey, and Denis Kuehnel. The first draft of the manuscript was written by Andreas Volk and all authors commented on subsequent versions of the manuscript. All authors read and approved the final manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}